Summary of prognostic factors for relapse incidence, survival, and leukemia-free survival identified in the multivariate analysis
Variable . | OS . | RR . | LFS . | ||||||
---|---|---|---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Age* | 1.771 | 1.287-2.436 | <.001 | 1.147 | 0.779-1.69 | NS | 1.482 | 1.047-2.089 | .027 |
WBC† | 1.429 | 1.021-2.0 | .038 | 1.22 | 0.779-1.910 | NS | 1.032 | 0.71-1.499 | NS |
FLT3 (ITD vs wild type) | 1.854 | 1.315-2.614 | <.001 | 2.395 | 1.569-3.654 | .000051 | 1.76 | 1.169-2.59 | .004 |
NPM1 (mut vs wild type) | 0.676 | 0.484-0.944 | .022 | 0.542 | 0.352-0.835 | .0054 | 0.739 | 0.512-1.067 | NS |
NPM1mut/FLT3wt‡ | 0.601 | 0.422-0.858 | .005 | 0.488 | 0.313-0.76 | .0015 | 0.615 | 0.418-0.905 | .014 |
FLT3-ITD ratio§ | 1.274 | 1.124-1.444 | <.001 | 1.604 | 1.427-1.8 | 2 × 10−15 | 1.363 | 1.162-1.598 | <.001 |
Variable . | OS . | RR . | LFS . | ||||||
---|---|---|---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Age* | 1.771 | 1.287-2.436 | <.001 | 1.147 | 0.779-1.69 | NS | 1.482 | 1.047-2.089 | .027 |
WBC† | 1.429 | 1.021-2.0 | .038 | 1.22 | 0.779-1.910 | NS | 1.032 | 0.71-1.499 | NS |
FLT3 (ITD vs wild type) | 1.854 | 1.315-2.614 | <.001 | 2.395 | 1.569-3.654 | .000051 | 1.76 | 1.169-2.59 | .004 |
NPM1 (mut vs wild type) | 0.676 | 0.484-0.944 | .022 | 0.542 | 0.352-0.835 | .0054 | 0.739 | 0.512-1.067 | NS |
NPM1mut/FLT3wt‡ | 0.601 | 0.422-0.858 | .005 | 0.488 | 0.313-0.76 | .0015 | 0.615 | 0.418-0.905 | .014 |
FLT3-ITD ratio§ | 1.274 | 1.124-1.444 | <.001 | 1.604 | 1.427-1.8 | 2 × 10−15 | 1.363 | 1.162-1.598 | <.001 |
All variables analyzed for all reported outcomes (response to induction, OS, RR, and LFS) are described in the text. HR, hazard ratio; NS, not significant; 95% CI, 95% confidence interval.
Below and above the median value: 47 years old.
Below and above the median: 19.9 × 109/L.
NPM1mut/FLT3wt genotype vs all other possibilities.
Considered as a continuous variable.